Skip to main content

Day: April 13, 2023

IntelGenx Announces Organizational Changes to Support Global Growth Strategy

SAINT LAURENT, Quebec, April 13, 2023 (GLOBE NEWSWIRE) — IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced various changes to its management team. Following the planned retirement of its founder and CEO, Horst G. Zerbe, PhD, the new executive leadership team is designed to support its continued global growth as a leading CDMO for oral films and transdermal products, and in particular, to further prepare it for the potential commercialization of RIZAFILM® VersaFilm®, a proprietary oral thin film formulation of rizatriptan benzoate (active ingredient in Merck & Co.’s Maxalt®), and Buprenorphine Buccal Film, a generic version of Belbuca® (buprenorphine buccal film), in the United States. The U.S. Food and Drug Administration (“FDA”) has assigned a Prescription...

Continue reading

PennantPark Floating Rate Capital Ltd.’s Unconsolidated Joint Venture, PennantPark Senior Secured Loan Fund I, LLC Completes $297.8 Million CLO, Marking Continued Growth in PennantPark’s Middle Market CLO Platform with Six CLOs Under Management

MIAMI, April 13, 2023 (GLOBE NEWSWIRE) — PennantPark Floating Rate Capital Ltd. (the “Company”) (NYSE: PFLT) (TASE: PFLT) today announced that PennantPark Senior Secured Loan Fund I, LLC (“PSSL”) through PSSL’s wholly-owned and consolidated subsidiary, PennantPark CLO VI, LLC (“CLO VI”) has closed a four-year reinvestment period, twelve-year final maturity $297.8 million debt securitization in the form of a collateralized loan obligation (“CLO”). The debt issued in the CLO (the “Debt”) is structured in the following manner:Class Par Amount($ in millions) % of Capital Structure Coupon Expected Rating(S&P) Issuance PriceA Notes $141,000,000 47.3% 3 Mo SOFR + 2.68% AAA 100.0%A Loans 30,000,000 10.1% 3 Mo SOFR + 2.68% AAA 100.0%B-1 28,000,000 9.4% 3 Mo SOFR + 3.75% AA 100.0%B-2 5,000,000 1.7% 7.634% AA 100.0%C 24,000,000 8.1% 3...

Continue reading

Genius Brands Files Form 10-K Annual Report

Provides Business Update CEO Letter BEVERLY HILLS, Calif., April 13, 2023 (GLOBE NEWSWIRE) — Genius Brands International, Inc. (“Genius Brands”) (NASDAQ: GNUS), a global brand management company that creates and licenses multimedia entertainment content for children, today announced that the Company had filed its Annual Report on Form 10-K with the US Securities and Exchange Commission. In addition, the Company’s Chairman and CEO, Andy Heyward provided a business update for the year ended December 31, 2022, in the form of a CEO letter, which can be accessed HERE. About Genius Brands International Genius Brands International, Inc. (Nasdaq: GNUS) is a leading global kids media company developing, producing, marketing and licensing branded children’s entertainment properties and consumer products for media and retail distribution....

Continue reading

Blink Charging Awarded $7 Million to Implement New Ride Share Service in New Jersey for Underserved Communities

Experienced ride share service provider receives grant to develop electric ride share program aimed at disadvantaged neighborhoods Miami Beach, FL, April 13, 2023 (GLOBE NEWSWIRE) — Blink Charging Co. (NASDAQ: BLNK) (“Blink” or the “Company”), a leading manufacturer, owner, operator and provider of electric vehicle (EV) charging equipment and services, and parent company to Blink Mobility LLC, an all-electric car-sharing service company, today announced the New Jersey Department of Environmental Protection (NJDEP), New Jersey Board of Public Utilities (NJBPU), and New Jersey Economic Development Authority (NJEDA), have awarded Blink $7 million in Regional Greenhouse Gas Initiative (RGGI) auction proceeds, to bring electric ride-sharing to New Jersey communities that lack access to reliable transportation. The award is part of the...

Continue reading

CFC To Host Conference Call on Fiscal Year 2023 Third-Quarter Financial Results

DULLES, Va., April 13, 2023 (GLOBE NEWSWIRE) — The National Rural Utilities Cooperative Finance Corporation (CFC) will hold an investor conference call and webcast Tuesday, April 18, at 10 a.m. Eastern Time. CFC CEO Andrew Don will provide a business update and CFC Senior Vice President and CFO Ling Wang will review CFC’s fiscal year 2023 third-quarter financial results. There are two ways to access the event:Live Webcast OptionVisit CFC’s investor Webcasts & Presentations page to join the webcast.Pre-registration is available for the event.Conference Call OptionDomestic: 800-239-9838 | International: 323-794-2551Participant Code: 6337060Callers also can view a PDF of the slide presentation by visiting the Webcasts & Presentations page on the day of the call. It will be posted just prior to the broadcast.A replay...

Continue reading

Annual general meeting of Aktieselskabet Schouw & Co.

Annual general meeting of Aktieselskabet Schouw & Co.The Company’s annual general meeting was held today at Hermans, Tivoli Friheden, DK-8000 Aarhus C, with some 600 people present. Report by the Board of DirectorsThe Chairman of the Board presented the Management’s report, including the previously announced full-year guidance. The Board’s report is not subject to a vote but was duly noted by the shareholders. Approval of annual report and allocation of profitThe shareholders voted to approve the annual report for 2022 including the Board’s recommendation for allocation of profit and the payment of a dividend of DKK 15 per share as well as the usual resolution to discharge the Board of Directors and the Executive Management from liability. Indicative vote on the remuneration reportThe Company’s Remuneration Report for 2022, which...

Continue reading

ZyVersa Therapeutics Announces Review Article Published in Frontiers in Pharmacology Addressing Microglial Inflammatory Activity as a Pharmacological Target in Mild Cognitive Impairment and Alzheimer’s Disease

During aging, the central nervous system (“CNS”) becomes more inflammatory, leading to activation of microglia (“CNS immune cells”), tissue damage, dysfunction, and senescence The article reviews microglial pathways, including the NLRP3 inflammasome pathway, which are promising drug targets for potential treatment of Alzheimer’s disease (“AD”) and slowing of cognitive agingWESTON, Fla., April 13, 2023 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces publication of a review article in Frontiers in Pharmacology addressing the NLRP3 inflammasome pathway as a potential drug target for treating mild cognitive impairment (“MCI”) and AD. In the paper titled, “Microglia:...

Continue reading

Endonovo Announces Partnership with Former NFL Dallas Cowboy Defensive Lineman

Los Angeles, CA, April 13, 2023 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV), a commercial stage developer of non-invasive medical devices, is pleased to announce its partnership with David Irving, former NFL (National Football League) defensive lineman, as brand ambassador for SofPulse®, a non-opioid pain and inflammation relief technology. Irving will share his experiences and results using SofPulse® for the management of his pain and inflammation. In studies, SofPulse® continues to show consistent benefits for patients suffering from chronic pain and joint injuries, including traumatic brain injuries (TBI), caused by sports-related injuries, falls, vehicle accidents, assaults and blasts. Irving will provide peer-to-peer and direct reviews on SofPulse® Pulsed Electro Magnetic Field (PEMF) therapy, which has shown...

Continue reading

Over 1,000 Cardiac Patients Treated with Genesis Robotic System

ST. LOUIS, April 13, 2023 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that over 1,000 cardiac arrhythmia patients have been treated using the Genesis Robotic Magnetic Navigation (RMN) system. Genesis RMN, the latest innovation in Stereotaxis’ robotic technology, was first used in late 2020 following regulatory clearances in the United States and Europe. Since then, physicians at eight global hospitals have treated over 1,000 patients using Genesis RMN. These hospitals include Helsinki University Central Hospital, Banner University Medical Center Phoenix, Princess Grace Hospital Center in Monaco, Missouri Baptist Medical Center, HonorHealth Scottsdale Shea Medical Center, Poland’s National Institute of Cardiology,...

Continue reading

Changes in the Management of Medicinos bankas UAB

Medicinos Bankas UAB (“Bank”), registration number 112027077, registered seat address: Pamėnkalnio 40, LT-01114 Vilnius, Lithuania. The Bank would like to inform you that after Aleksejus Tonkich resignation, on 12 of April 2023 the Supervisory Board of the Bank dismissed Mr. Tonkich from the position of a member of the Management Board from 2 of May 2023. Mr. Tonkich has been a member of the Management Board of Medicinos bankas UAB since 4 th of May of 2020. For more information please contact: I.Šerys Head of Marketing and Communication, ph.: + 370 610 21 691, e-mail: media@medbank.lt

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.